Roberta Vitale

Ms. Roberta Vitale


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RVRoberta Vitale
Roberta Vitale
STEFANIA MARZOCCOSTEFANIA MARZOCCO
STEFANIA MARZOCCO
APAda Popolo
Ada Popolo
Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulness. Different studies focused only on the effects of long-term Doxo administration, but recent data show that cardiomyocyte damage is an early event induced by Doxo after a single administration that can be followed by progressive functional decline, leading to overt heart failure. The knowledge of molecular mechanisms involved in the early stage of Doxo-induced cardiotoxicity is of paramount importance to treating and/or preventing it. This review aims to illustrate several mechanisms thought to underlie Doxo-induced cardiotoxicity, such as oxidative and nitrosative stress, inflammation, and mitochondrial dysfunction. Moreover, here we report data from both in vitro and in vivo studies indicating new therapeutic strategies to prevent Doxo-induced cardiotoxicity.

27 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RVRoberta Vitale
Roberta Vitale
STEFANIA MARZOCCOSTEFANIA MARZOCCO
STEFANIA MARZOCCO
APAda Popolo
Ada Popolo
Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulness. Different studies focused only on the effects of long-term Doxo administration, but recent data show that cardiomyocyte damage is an early event induced by Doxo after a single administration that can be followed by progressive functional decline, that lead to overt heart failure. The knowledge of molecular mechanisms involved in the early stage of Doxo induced cardiotoxicity is of paramount importance to treat and/or prevent it. This review aims to illustrate several mechanisms considered to underlie Doxo-induced cardiotoxicity, such as oxidative and nitrosative stress, inflammation, and mitochondrial dysfunction. Moreover, here we report data from both in vitro and in vivo studies indicating new therapeutic possibilities to prevent Doxo-induced cardiotoxicity.

Verified
Journal Article
Open access
PDF file
RVRoberta Vitale
Roberta Vitale
MMMariangela Mazzone
Mariangela Mazzone
Maria Carmela Di MarcantonioMaria Carmela Di Marcantonio
Maria Carmela Di Marcantonio
STEFANIA MARZOCCOSTEFANIA MARZOCCO
STEFANIA MARZOCCO
GMGabriella Mincione
Gabriella Mincione
APAda Popolo
Ada Popolo
Oxidative stress and mitochondrial dysfunction play a key role in the early stage of Doxorubicin (Doxo)-induced cardiotoxicity. Our study investigated the potential cardioprotective role of Simvastatin (Sim), widely known for its antioxidant properties, in an in vitro model of Doxo-induced acute cardiotoxicity. Human Cardiomyocytes (HCMs) were treated with Sim (10 µM, 4 h) and then co-exposed to Doxo (1 µM) and Sim for 20 h. Our data showed that Sim co-treatment significantly (p < 0.05) reduced both cytosolic and mitochondrial Doxo-induced reactive oxygen species overproduction. In Sim co-treated cells, significant reductions in nuclear factor erythroid 2-related factor 2 (Nrf2) gene expression (p < 0.01) and catalase (CAT), heme-oxygenase 1 (HO-1), and superoxide dismutase 2 (SOD2) levels (p < 0.05) compared to Doxo-treated cells were also demonstrated, suggesting a decreased need for compensatory antioxidant defense responses. Moreover, significant reductions in Doxo-induced mitochondrial calcium overload, mitochondrial membrane depolarization (p < 0.005), and apoptosis (p < 0.005) confirmed the protective effects of Sim co-treatment on cardiomyocytes. These data confirm that Sim could be a valuable therapeutic strategy for reducing Doxo-induced HCM damage, preventing the development of dilated cardiomyopathy and long-term heart damage, which are the main limitations of anthracycline use. Finally, real-time PCR analysis revealed that Sim co-treatment significantly reduced (p < 0.001) the Doxo-induced overexpression of MAP4K4, a mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) involved in oxidative stress-induced cell death, thus suggesting the involvement of other molecular mechanisms in Sim-mediated cardioprotection.

8 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
RVRoberta Vitale
Roberta Vitale
RRRosaria Margherita Rispoli
Rosaria Margherita Rispoli
Maria Carmela Di MarcantonioMaria Carmela Di Marcantonio
Maria Carmela Di Marcantonio
BPBarbara Pala
Barbara Pala
STEFANIA MARZOCCOSTEFANIA MARZOCCO
STEFANIA MARZOCCO
APAda Popolo
Ada Popolo
Background/Objectives: Clinical application of Doxorubicin (Doxo) is limited by cardiotoxicity, a process strongly associated with an interplay between oxidative stress and inflammatory signaling, particularly Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and Nucleotide oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome engagement. Identifying strategies capable of mitigating these interconnected pathways is of critical importance in cardio-oncology. Simvastatin (SIM) is a promising option since it modulates oxidative stress, inflammation, and cell death through its pleiotropic effects, so this study aimed to evaluate whether SIM attenuates Doxo-induced inflammatory responses. Methods: Human Cardiomyocyte (HCM) cells were pre-treated with SIM (10 µM) for 4 h and then co-exposed to SIM and Doxo (1 µM) for 20 h. Cytofluorimetric analysis was used to evaluate inducible nitric oxide synthase (iNOS), Connexin 43 (Cx43), and Cx43 phosphorylated at Serine 368 (pS368Cx43) levels. Real-time qPCR was performed to evaluate iNOS gene expression, while Nitric oxide (NO) release was evaluated by spectrophotometric analysis. Interleukin (IL)-1β, IL-18, IL-6, tumor necrosis factor alpha (TNF-α) production, and NLRP3 levels were evaluated by means of ELISA assay. Expression levels of inhibitor of nuclear factor kappa B alpha (IκB-α), Caspase-1, and Gasdermin D (GSDMD) were evaluated by Western Blot analysis. Nuclear translocation of NF-κB was evaluated by immunofluorescence assay. Results: In our experimental model, SIM significantly (p < 0.01) reduced Doxo-induced nitrite release, as well as iNOS gene expression (p < 0.05) and protein levels (p < 0.01). SIM also markedly attenuated Doxo-induced NF-κB signaling, pro-inflammatory cytokines production (TNF-α and IL-6, p < 0.01), and inflammosome-related responses (cleaved caspase-1, IL-1β, N-terminal domain of GSDMD), and NLRP3 expression p < 0.05). Additionally, SIM significantly attenuated the overexpression of Cx43 and its phosphorylated form (pS368Cx43), which are responsible for impairing intercellular communication and electrical coupling in cardiomyocytes and contribute to arrhythmias and conduction abnormalities characteristic of acute Doxo-induced cardiotoxicity. Conclusions: Overall, these findings demonstrate that SIM exerts a multifaceted cardioprotective effect against Doxo-induced injury, thereby targeting interconnected inflammatory and pro-arrhythmic pathways implicated in Doxo cardiotoxicity.

31 August 2026 in Plants
Verified
Journal Article
Open access
PDF file
ACANNA CACCIOLA
ANNA CACCIOLA
SAShiva Pouramin Arabi
Shiva Pouramin Arabi
VDValeria D’Angelo
Valeria D’Angelo
GDGiuliana Donadio
Giuliana Donadio
FRFrancesco Maria Raimondo
Francesco Maria Raimondo
Nunziatina De TommasiNunziatina De Tommasi
Nunziatina De Tommasi
Crataegus L. (Rosaceae) comprises several species rich in nutrients and bioactive compounds with nutraceutical relevance. The present study aimed to investigate the polyphenolic profile, antioxidant activity, and in vitro antihyperglycemic-related activity of fruits from 11 Crataegus taxa collected in Western Sicily, a region characterized by a high diversity of this genus. Total polyphenol quantification indicated that, among the tested extracts, Crataegus laciniata exhibited the highest content (25.54 mg GAE/g). Using high-resolution Orbitrap Q-Exactive PLUS ESI-MS instrument (Thermo Fisher Scientific, Waltham, MA, USA), a comprehensive phytochemical characterization was performed. Hyperoside quantification revealed that Crataegus aff. insengae, Crataegus zichichii, and Crataegus drepanensis are rich in this bioactive compound (1.47, 1.22, 1.22 mg/g DW). Multivariate analysis, including principal component analysis (PCA), highlighted hyperoside and vitexin as the main contributors to sample differentiation. Additionally, Crataegus laciniata, Crataegus drepanensis, and Crataegus aff. insengae showed the highest antioxidant activity in chemical assays (DPPH, ABTS, and FRAP) and in Caco-2 and H9c2 cell models through the modulation of intracellular reactive oxygen species (ROS). Regarding antihyperglycemic-related activity, Crataegus laciniata, Crataegus azarolus var. azarolus, and Crataegus drepanensis extracts showed the best inhibitory activity against α-glucosidase and α-amylase. Overall, the study highlights the value of Crataegus fruits as sources of bioactive compounds for food and nutraceutical research and supports their further valorization.